During the yearly London Calling conference, organised by Oxford Nanopore Technologies, Cyclomics CEO Jeroen de Ridder reported on recent results obtained from their CyclomicsSeq platform. The London Calling conference is a yearly event, that attracts over 600 academic and industrial researchers, who use the Oxford Nanopore sequencing platform for applications ranging from genome research, pathogen detection, plant breeding and genetic diagnostics. Oxford Nanopore invited Cyclomics to present their recent work on clinical use of the CyclomicsSeq blood-based cancer detection platform, during a main stage plenary session.
The Cyclomics presentation highlighted results from a first clinical trial - sponsored by the Oncode Institute - focused on detecting recurring tumors in patients with head-and-neck cancer in a collaborative study with the University Medical Center Utrecht. Dr de Ridder informed the audience on breakthrough data demonstrating extremely sensitive and longitudinal measurement of TP53 mutations in the blood of head-and-neck cancer patients. Further results are expected by the end of 2019, including a thorough comparison of CyclomicsSeq and imaging-based cancer recurrence detection.